A phase 2 prospective study suggested that a PD-1 inhibitor had CNS efficacy, with an intracranial ORR of 29.7% and PFS of 2.3 months in PD-L1-positive NSCLC patients with untreated BMs (16). Here, CD274 is linked to non-small cell lung carcinoma.